An antimicrobial coating system and method are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two of the cyclic groups may include quaternary ammonium moieties. In some embodiments, a method may include applying an antimicrobial coating to an oral surface, a surface of a construction substrate, a surface of a marine substrate, a surface of a medical device, or a surface of a personal care device. The protective coating may be antimicrobial. A protective coating may include antimicrobial bridged polycyclic compounds. Bridged polycyclic compounds may include quaternary ammonium compounds. Bridged polycyclic compounds based coating systems may impart self-cleaning properties to a surface (e.g., a tooth surface).

The present invention is related to a class of stable 2D covalent organic frameworks with multiple dimethyl amino groups that can trap carbon dioxide at ambient temperature and pressure, and an economical, environmentally-friendly process for the generation of transient surface charges and subsequent self-exfoliation of the COF into ultrathin nanosheets. The said exfoliated material possess activity against pathogenic bacteria. The invention further discloses a carbon dioxide induced exfoliation process that is completely reversible upon heat treatment, whereby control over bacterial growth is achieved via an efficient antibiotic switch.

The present invention is related to a class of stable 2D covalent organic frameworks with multiple dimethyl amino groups that can trap carbon dioxide at ambient temperature and pressure, and an economical, environmentally-friendly process for the generation of transient surface charges and subsequent self-exfoliation of the COF into ultrathin nanosheets. The said exfoliated material possess activity against pathogenic bacteria. The invention further discloses a carbon dioxide induced exfoliation process that is completely reversible upon heat treatment, whereby control over bacterial growth is achieved via an efficient antibiotic switch.

The present invention is directed to a process for the preparation of phosphoric acid loaded covalent organic framework (PA@Tp-Azo and PA@Tp-Stb) with high stability and high proton conductivity.

The present invention is directed to a process for the preparation of phosphoric acid loaded covalent organic framework (PA@Tp-Azo and PA@Tp-Stb) with high stability and high proton conductivity.

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Provided herein are compounds, such as compounds of Formulae (I), (I), (XI), (XII), and (XIII), and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of agents, including polynucleotides such as mRNA, for the treatment and/or prevention of various diseases and conditions (e.g., genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, spleen diseases, lung diseases, painful conditions, psychiatric disorders, musculoskeletal diseases, metabolic disorders, inflammatory diseases, and autoimmune diseases). Also provided herein are methods of synthesis of compounds of Formulae (I), (XI), (XII), (XIII), and (VIII).

Provided herein are compounds, such as compounds of Formulae (I), (I), (XI), (XII), and (XIII), and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of agents, including polynucleotides such as mRNA, for the treatment and/or prevention of various diseases and conditions (e.g., genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, spleen diseases, lung diseases, painful conditions, psychiatric disorders, musculoskeletal diseases, metabolic disorders, inflammatory diseases, and autoimmune diseases). Also provided herein are methods of synthesis of compounds of Formulae (I), (XI), (XII), (XIII), and (VIII).